Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.
Thomas D
,
Gut B
,
Karsai S
,
Wimmer AB
,
Wu K
,
Wendt-Nordahl G
,
Zhang W
,
Kathöfer S
,
Schoels W
,
Katus HA
,
Kiehn J
,
Karle CA
.
???displayArticle.abstract???
Tamoxifen is a nonsteroidal antiestrogen that is commonly used in the treatment of breast cancer. Although antiestrogenic drugs are generally believed not to cause acquired long QT syndrome (LQTS), concerns have been raised by recent reports of QT interval prolongation associated with tamoxifen treatment. Since blockade of human ether-a-go-go-related gene (HERG) potassium channels is critical in the development of acquired LQTS, we investigated the effects of tamoxifen on cloned HERG potassium channels to determine the electrophysiological basis for the arrhythmogenic potential of this drug. HERG channels were heterologously expressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage clamp technique. Tamoxifen blocked HERG potassium channels with an IC(50) value of 45.3 microM. Inhibition required channel opening and unblocking occurred very slowly. Analysis of the voltage-dependence of block revealed loss of inhibition at positive membrane potentials, indicating that strong channel inactivation prevented block by tamoxifen. No marked changes in electrophysiological parameters such as voltage-dependence of activation or inactivation, or inactivation time constant could be observed, and block was not frequency-dependent. This study demonstrates that HERG potassium channels are blocked by the antiestrogenic drug tamoxifen. We conclude that HERG current inhibition might be an explanation for the QT interval prolongation associated with this drug.
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999, Pubmed,
Xenbase
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999,
Pubmed
,
Xenbase
Bergan,
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
1999,
Pubmed
Berman,
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
1995,
Pubmed
Bril,
Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
1996,
Pubmed
Chouabe,
HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.
1998,
Pubmed
Clancy,
K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation.
2003,
Pubmed
Daniel,
Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry.
1979,
Pubmed
Ficker,
Molecular determinants of dofetilide block of HERG K+ channels.
1998,
Pubmed
,
Xenbase
Ficker,
Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome.
2000,
Pubmed
,
Xenbase
Fisher,
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
1998,
Pubmed
Hutchison,
Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro.
2001,
Pubmed
Kamiya,
Open channel block of HERG K(+) channels by vesnarinone.
2001,
Pubmed
,
Xenbase
Kang,
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.
2001,
Pubmed
Karle,
Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
2001,
Pubmed
,
Xenbase
Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase
Kiehn,
Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
1996,
Pubmed
,
Xenbase
Liu,
The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes.
1998,
Pubmed
McDonald,
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
1991,
Pubmed
Millward,
Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.
1992,
Pubmed
Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase
Murphy,
Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
1987,
Pubmed
Napolitano,
Torsade de pointes. Mechanisms and management.
1994,
Pubmed
NULL,
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
1992,
Pubmed
Numaguchi,
Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
2000,
Pubmed
O'Day,
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
2001,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Scherer,
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
2002,
Pubmed
,
Xenbase
Shang,
Molecular determinants for the tissue specificity of SERMs.
2002,
Pubmed
Smith,
The inward rectification mechanism of the HERG cardiac potassium channel.
1996,
Pubmed
Suessbrich,
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole.
1996,
Pubmed
,
Xenbase
Suessbrich,
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Teschemacher,
Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
1999,
Pubmed
Thomas,
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
2001,
Pubmed
,
Xenbase
Thomas,
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
1999,
Pubmed
,
Xenbase
Thomas,
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
2002,
Pubmed
,
Xenbase
Trump,
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
1992,
Pubmed
Viskin,
Long QT syndromes and torsade de pointes.
1999,
Pubmed
Warmke,
A family of potassium channel genes related to eag in Drosophila and mammals.
1994,
Pubmed
Weerapura,
A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
2002,
Pubmed
,
Xenbase
Zhang,
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
1999,
Pubmed
